Amphastar Pharmaceuticals (AMPH) Q3 2024 earnings summary

Executive summary

• Net revenues for Q3 2024 reached $191.2 million, a 6% year-over-year increase, driven by strong sales of BAQSIMI® and Primatene MIST®, and the transition of BAQSIMI® distribution from Lilly.

• Net income for Q3 2024 was $40.4 million ($0.78 per share), down from $49.2 million in Q3 2023, reflecting higher operating and R&D expenses and lower gross margins.

• The company focuses on sustainable long-term growth through proprietary products, biosimilars, and strategic acquisitions, with a fully integrated business model covering R&D, manufacturing, and distribution.

• Operating cash flow for the nine months ended September 30, 2024, was $184.4 million, supporting ongoing investments and share repurchases.

• Recent launches include Albuterol MDI and Rextovy, with continued expansion of the branded and biosimilar portfolio.

Financial highlights

• Q3 2024 net revenues: $191.2 million, up 6% year-over-year; nine-month revenues: $545.4 million, up 17%.

• Gross margin declined to 53% from 60% year-over-year due to higher labor and component costs and inventory adjustments.

• Net income decreased 18% to $40.4 million; adjusted net income was $49.6 million ($0.96 per share).

• Operating expenses rose 26% year-over-year in Q3 2024, mainly from increased R&D and marketing for BAQSIMI®.

• Cash and cash equivalents at September 30, 2024, were $192.1 million; working capital increased to $386.9 million.

Outlook and guidance

• Management expects continued growth in higher-margin products, including BAQSIMI®, Primatene MIST®, vasopressin, ganirelix, and albuterol.

• Primatene MIST® is on track for $100 million in annual sales by year-end 2024, with further growth initiatives planned for 2025.

• BAQSIMI® peak sales are projected at $250–$275 million, with current annual sales trending close to base case expectations.

• R&D expenses are projected to rise due to increased clinical trial activity for insulin and inhalation product candidates.

• Revenues delayed by Hurricane Helene ($2–4 million) are expected to be recognized in Q4 2024.